Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Overview

Journal Oncology

Specialty Oncology

Date 2018 Jul 25

PMID 30041177

Citations 6

Authors

Giovanna Catania

Paola Malaguti

Simona Gasparro

Francesco Cognetti

Antonello Vidiri

Alessandra Fabi

Affiliations

Soon will be listed here.

Abstract

Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.

Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile.

Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response.

Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.

Citing Articles

An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.

Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J Cancer Chemother Pharmacol. 2024; 94(6):807-813.

PMID: 39422741 PMC: 11573798. DOI: 10.1007/s00280-024-04711-2.

An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.

Meng X, Wang M, Zhang K, Sui D, Chen M, Xu Z AAPS PharmSciTech. 2022; 23(8):285.

PMID: 36258152 DOI: 10.1208/s12249-022-02432-4.

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer.

Sabatier R, Martin J, Vicier C, Guerin M, Monneur A, Provansal M J Clin Med. 2021; 10(6).

PMID: 33803894 PMC: 8003126. DOI: 10.3390/jcm10061272.

A view on the landscape of breast cancer brain metastases.

Malani R CNS Oncol. 2020; 9(3):CNS59.

PMID: 32990026 PMC: 7546123. DOI: 10.2217/cns-2020-0013.

Eribulin and Confusion: A Previously Unknown Drug Side-Effect.

Sheikh A, Perisetti A, Javed N, Shekhar R Eur J Case Rep Intern Med. 2020; 7(9):001708.

PMID: 32908828 PMC: 7473676. DOI: 10.12890/2020_001708.

References

Nieder C, Aandahl G, Dalhaug A . A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med. 2012; 2012:537183. PMC: 3431070. DOI: 10.1155/2012/537183. View

Borgonovo K, Petrelli F, Cabiddu M, Ghilardi M, Coinu A, Seghezzi S . Long response to eribulin in breast cancer: a case report. Future Oncol. 2015; 11(15 Suppl):3-8. DOI: 10.2217/fon.15.146. View

van Vulpen M, Kal H, Taphoorn M . Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002; 9(4):683-8. View

McTyre E, Scott J, Chinnaiyan P . Whole brain radiotherapy for brain metastasis. Surg Neurol Int. 2013; 4(Suppl 4):S236-44. PMC: 3656558. DOI: 10.4103/2152-7806.111301. View

Cardoso F, Bedard P, Winer E, Pagani O, Senkus-Konefka E, Fallowfield L . International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009; 101(17):1174-81. PMC: 2736293. DOI: 10.1093/jnci/djp235. View

Matsuoka H, Tsurutani J, Tanizaki J, Iwasa T, Komoike Y, Koyama A . Regression of brain metastases from breast cancer with eribulin: a case report. BMC Res Notes. 2013; 6:541. PMC: 3878316. DOI: 10.1186/1756-0500-6-541. View

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman P . Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014; 148(3):553-61. PMC: 4243003. DOI: 10.1007/s10549-014-3144-y. View

Ekenel M, Hormigo A, Peak S, DeAngelis L, Abrey L . Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007; 85(2):223-7. DOI: 10.1007/s11060-007-9409-0. View

Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y . Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014; 105(10):1334-42. PMC: 4462349. DOI: 10.1111/cas.12488. View

10.

Kaufman P, Awada A, Twelves C, Yelle L, Perez E, Velikova G . Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015; 33(6):594-601. PMC: 4463422. DOI: 10.1200/JCO.2013.52.4892. View

11.

Qin D, Zheng R, Tang J, Li J, Hu Y . Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990; 19(6):1507-10. DOI: 10.1016/0360-3016(90)90364-p. View

12.

Minisini A, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E . Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis. 2013; 30(8):951-6. DOI: 10.1007/s10585-013-9594-5. View

13.

Dawood S, Gonzalez-Angulo A . Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist. 2013; 18(6):675-84. PMC: 4063393. DOI: 10.1634/theoncologist.2012-0438. View

14.

Soliman H, Das S, Larson D, Sahgal A . Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget. 2016; 7(11):12318-30. PMC: 4914287. DOI: 10.18632/oncotarget.7131. View

15.

Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I . Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014; 5(5):320-7. PMC: 3982178. DOI: 10.7150/jca.8748. View

16.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F . ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014; 23(5):489-502. DOI: 10.1016/j.breast.2014.08.009. View

17.

Bart J, Nagengast W, Coppes R, Wegman T, van der Graaf W, Groen H . Irradiation of rat brain reduces P-glycoprotein expression and function. Br J Cancer. 2007; 97(3):322-6. PMC: 2360314. DOI: 10.1038/sj.bjc.6603864. View

18.

Fabi A, Vidiri A, Ferretti G, Felici A, Papaldo P, Carlini P . Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?. Cancer Invest. 2006; 24(4):466-8. DOI: 10.1080/07357900600705805. View

19.

Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K . Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23. DOI: 10.1016/S0140-6736(11)60070-6. View

20.

Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S . Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today. 2015; 46(7):821-6. DOI: 10.1007/s00595-015-1252-x. View